The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs
Open accessAbstract
Severe acute respiratory syndrome (SARS) is an infectious disease caused by a newly identified human coronavirus (SARS-CoV). Currently, no effective drug exists to treat SARS-CoV infection. In this study, we investigated whether a panel of commercially available antiviral drugs exhibit in vitro anti-SARS-CoV activity. A drug-screening assay that scores for virus-induced cytopathic effects on cultured cells was used. Tested were 19 clinically approved compounds from several major antiviral pharmacologic classes: nucleoside analogs, interferons, protease inhibitors, reverse transcriptase inhibitors, and neuraminidase inhibitors. Complete inhibition of cytopathic effects of SARS-CoV in culture was observed for interferon subtypes, b-1b, a-n1, a-n3, and human leukocyte interferon a. These findings support clinical testing of approved interferons for the treatment of SARS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of a novel coronavirus in patients with severe acute respiratory syndrome
Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H.-R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R. A. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030747 · Cited by 4,574
Higgins, P. G., Phillpotts, R. J., Scott, G. M., Wallace, J., Bernhardt, L. L., & Tyrrell, D. A. (1983) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.24.5.713 · Cited by 90
Cited by
Hung, I. F.-N., Lung, K.-C., Tso, E. Y.-K., Liu, R., Chung, T. W.-H., Chu, M.-Y., Ng, Y.-Y., Lo, J., Chan, J., Tam, A. R., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31042-4 · Cited by 1,455
Potential interventions for novel coronavirus in China: A systematic review
Zhang, L., & Liu, Y. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25707 · Cited by 1,348
Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection
Cheng, V. C. C., Lau, S. K. P., Woo, P. C. Y., & Yuen, K. Y. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00023-07 · Cited by 1,192
Severe acute respiratory syndrome
Peiris, J. S. M., Guan, Y., & Yuen, K. Y. (2004) · Nature Medicine · doi:10.1038/nm1143 · Cited by 1,139
Pillaiyar, T., Manickam, M., Namasivayam, V., Hayashi, Y., & Jung, S.-H. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01461 · Cited by 775
Sharma, A., Tiwari, S., Deb, M. K., & Marty, J. L. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106054 · Cited by 705
An interferon‐γ‐related cytokine storm in SARS patients
Huang, K., Su, I., Theron, M., Wu, Y., Lai, S., Liu, C., & Lei, H. (2005) · Journal of Medical Virology · doi:10.1002/jmv.20255 · Cited by 679
COVID-19: A promising cure for the global panic
Vellingiri, B., Jayaramayya, K., Iyer, M., Narayanasamy, A., Govindasamy, V., Giridharan, B., Ganesan, S., Venugopal, A., Venkatesan, D., Ganesan, H., et al. (2020) · Science of The Total Environment · doi:10.1016/j.scitotenv.2020.138277 · Cited by 636
Thomas, T., Stefanoni, D., Reisz, J. A., Nemkov, T., Bertolone, L., Francis, R. O., Hudson, K. E., Zimring, J. C., Hansen, K. C., Hod, E. A., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140327 · Cited by 586
Small molecules targeting severe acute respiratory syndrome human coronavirus
Wu, C.-Y., Jan, J.-T., Ma, S.-H., Kuo, C.-J., Juan, H.-F., Cheng, Y.-S. E., Hsu, H.-H., Huang, H.-C., Wu, D., Brik, A., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403596101 · Cited by 521
Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction
HO, T., WU, S., CHEN, J., LI, C., & HSIANG, C. (2007) · Antiviral Research · doi:10.1016/j.antiviral.2006.04.014 · Cited by 516
COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons
Nile, S. H., Nile, A., Qiu, J., Li, L., Jia, X., & Kai, G. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.05.002 · Cited by 440
Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., O’Meara, M. J., Guo, J. Z., Swaney, D. L., Tummino, T. A., Huettenhain, R., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.22.002386 · Cited by 395
Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options
McCreary, E. K., & Pogue, J. M. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa105 · Cited by 334
Human Coronaviruses: What Do They Cause?
Van Der Hoek, L. (2007) · Antiviral Therapy · doi:10.1177/135965350701200s01.1 · Cited by 331
The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro
Wang, X., Cao, R., Zhang, H., Liu, J., Xu, M., Hu, H., Li, Y., Zhao, L., Li, W., Sun, X., et al. (2020) · Cell Discovery · doi:10.1038/s41421-020-0169-8 · Cited by 329
Alanagreh, L., Alzoughool, F., & Atoum, M. (2020) · Pathogens · doi:10.3390/pathogens9050331 · Cited by 291
Current status of potential therapeutic candidates for the COVID-19 crisis
Zhang, J., Xie, B., & Hashimoto, K. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.04.046 · Cited by 283
Coleman, C. M., Sisk, J. M., Mingo, R. M., Nelson, E. A., White, J. M., & Frieman, M. B. (2016) · Journal of Virology · doi:10.1128/jvi.01429-16 · Cited by 257
Muslim, S., Nasrin, N., Alotaibi, F. O., Prasad, G., Singh, S. K., Alam, I., & Mustafa, G. (2020) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00407-9 · Cited by 25
Metadata
- Authors
- Tan, E. L. C., Ooi, E. E., Lin, C.-Y., Tan, H. C., Ling, A. E., Lim, B., & Stanton, L. W.
- Venue
- Emerging Infectious Diseases
- Published
- 2004-04
- Volume
- 10
- Issue
- 4
- Pages
- 581-586
- ISSN
- 1080-6040 (ISSN-L)
- 1080-6059
- OpenAlex
- W4205552948
- Cited by
- 237
- References
- 2
- FWCI
- 10.17
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.